Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management
Open Access
- 4 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 10 (11), 1-12
- https://doi.org/10.1038/s41408-020-00370-7
Abstract
Multiple myeloma (MM) is associated with increased risk of infection, but little is known regarding antibody levels against specific bacteria. We assessed levels of polyclonal immunoglobulin and antibacterial antibodies in patients recruited to the TEAMM trial, a randomised trial of antibiotic prophylaxis at the start of anti-myeloma treatment. Polyclonal IgG, IgA and IgM levels were below the reference range in 71%, 83% and 90% of 838 MM patients at diagnosis. Anti-vaccine targeted tetanus toxoid antibodies were protective in 95% of 193 healthy controls but only 41% of myeloma patients. In healthy controls, protective antibodies against 6/12 pneumococcal serotypes, haemophilus and meningococcus A were present in 67%, 41% and 56% compared to just 15%, 21% and 17% of myeloma patients. By 1 year, myeloma patients IgG levels had recovered for 57% of patients whilst the proportion with protective levels of IgG against thymus-dependent protein antigen tetanus toxoid had changed little. In contrast the proportions of patients with protective levels against thymus independent polysaccharide antigens pneumococcus, haemophilus and meningococcus had fallen from 15 to 7%, 21 to 0% and 17 to 11%. Findings highlight the need for strategies to protect patients against bacterial infections during therapy and vaccination programmes during remission.Keywords
Funding Information
- DH | NIHR | Efficacy and Mechanism Evaluation Programme (14/24/04)
- DH | NIHR | Health Technology Assessment Programme (08/116/69)
This publication has 26 references indexed in Scilit:
- Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCTHealth Technology Assessment, 2019
- Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantationAnnals of Hematology, 2019
- Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trialsLeukemia, 2018
- Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institutionLeukemia & Lymphoma, 2017
- Causes of early death in multiple myeloma patients who are ineligible for high‐dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma DatabaseAmerican Journal of Hematology, 2015
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patientsHaematologica, 2014
- Measurement of antibodies to pneumococcal, meningococcal and haemophilus polysaccharides, and tetanus and diphtheria toxoids using a 19-plexed assayJournal of Immunological Methods, 2012
- Multiple Myeloma and Polyclonal HypogammaglobulinaemiaActa Medica Scandinavica, 2009
- Multiple MyelomaNew England Journal of Medicine, 2004
- Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of AgeNew England Journal of Medicine, 1977